pdufa.bio

EPKINLY (epcoritamab-bysp)

Page updated ·next FDA decision on the calendar ·Data as of Oct 11, 2026 9:31 PM ET

EPKINLY (epcoritamab-bysp) The FDA approved it on Nov 18, 2025. 2 FDA decisions on record below. Every date links its source.

ABBV catalyst hub · GMAB catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 2 catalyst events for this program: 0 upcoming and 2 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

FDA decision · Nov 18, 2025 ✓ ApprovedABBVFDA decision · Nov 18, 2025 ✓ ApprovedGMAB

Questions

When is EPKINLY (epcoritamab-bysp)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for EPKINLY (epcoritamab-bysp); 2 FDA decisions are on record below.

What happened at EPKINLY (epcoritamab-bysp)'s most recent FDA decision?

On Nov 18, 2025 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has EPKINLY (epcoritamab-bysp) been approved by the FDA?

Yes. The FDA approved an application for EPKINLY (epcoritamab-bysp) on Nov 18, 2025; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.